Business UpdateJun 11, 2026, 07:31 AM
Helus Pharma CMO to Speak at H.C. Wainwright Neuro Conference
AI Summary
Helus Pharma, the commercial operating name of Cybin Inc., announced that its Chief Medical Officer, Amir Inamdar, will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 15-16, 2026. The clinical-stage pharmaceutical company is focused on developing novel serotonergic agonists (NSAs) for mental health conditions. Its pipeline includes HLP003 in Phase 3 for major depressive disorder, which has Breakthrough Therapy Designation, and HLP004 in Phase 2 for generalized anxiety disorder.
Key Highlights
- Helus Pharma's Chief Medical Officer, Amir Inamdar, will participate in a fireside chat.
- The event is the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference.
- The fireside chat will be available on-demand starting June 15, 2026, at 7:00 a.m. EDT.
- Helus Pharma is developing HLP003 in Phase 3 for major depressive disorder.
- HLP003 has received Breakthrough Therapy Designation from the U.S. FDA.
- The company is also developing HLP004 in Phase 2 for generalized anxiety disorder.
Price Impact
More from HELP